跳至主要内容
临床试验/ACTRN12612000145808
ACTRN12612000145808撤回未知

A prospective, randomised validation of corneal epithelial cell-counting with two instruments after 4 hours of bilateral contact lens wear and a prospective, randomised, masked, parallel group comparison of two commercially-available tear supplements utilising different preservatives, on corneal epithelial cell shedding when tear supplements are used unilaterally for two weeks

Allergan, Inc0 个研究点目标入组 25 人开始时间: 2012年2月1日最近更新:
适应症

试验速览

阶段
未知
状态
撤回
发起方
Allergan, Inc
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Diagnosis
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent.
  • -Be at least 18 years old, male or female.
  • -Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator.
  • -Have ocular health findings considered to be normal” and which would not prevent the participant from safely wearing contact lenses.
  • -Be an experienced contact lens wearer (but willing to not wear contact lenses for the duration of the trial, except, during stage visits 2-3) or a non lens wearer (but willing to wear plano lenses for approximately four hours on one day during stage 1 visits 2-3).

排除标准

  • -Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses.
  • -Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.
  • -Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial.
  • -Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant’s ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial.
  • NB: Systemic antihistamines are allowed on an as needed basis”, provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.
  • -Eye surgery within 12 weeks immediately prior to enrolment for this trial.
  • -Previous corneal refractive surgery.
  • -Known allergy or intolerance to ingredients in any of the clinical trial products.
  • -Currently enrolled in another clinical trial.
  • -Participation in a clinical trial within the previous 2 weeks for dispensing studies and 48 hours between in-house studies.
  • -Not willing to not wear contact lenses for the duration of the clinical trial.
  • -Pregnancy* (either at enrolment or during the course of the trial). Formal testing of pregnancy is not required. A participant’s verbal report is sufficient
  • -The Investigator may, at his / her discretion, exclude anyone who they believe may not be able to fulfil the clinical trial requirements or it is believed to be in the participant’s best interests.

研究者

发起方
Allergan, Inc

相似试验

A comparison of two commercially-available eye drops... | 临床试验